The Journal of Abnormal Child Psychology devoted 136 pages of its January issue to papers describing the new condition called...
Tafasitamab, an anti-CD19 immunotherapy, is used with lenalidomide for patients with autologous stem cell transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma based on the results of the phase II L-MIND study (NCT02399085).
The overarching objective of this protocol is to identify and understand the neural and pain processing mechanisms by which youth with migraine improve in response to preventive treatment.
BioXcel Therapeutics, Inc., announced promising results for BXCL 501, the Company’s proprietary, orally dissolving film of dexmedetomidine under investigation for the treatment of agitation, in Part 1 of its Phase III SERENITY III trial conducted in institutional settings for acute treatment of bipolar disorders- or schizophrenia-associated agitation
The National Institute for Health and Care Excellence (NICE) has changed its mind regarding Repatha (evolocumab) from Amgen. In a...
Incyte announced that Health Canada has granted a Notice of Compliance with conditions for Minjuvi (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).
World Mental Health Day, recognised by the World Health Organisation, takes place today 10 October 2017.
People with haemophilia have an increased risk of acute and chronic pain, and long-term disability, associated with bleeds...
Incyte and MorphoSys AG announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody.